Paratex Names Kris Peterson To Board
This article was originally published in Scrip
Executive Summary
Paratek Pharmaceuticals, Inc. has appointed Kris Peterson to its board of directors. Peterson has over 30 years' experience and joins Paratek from Valeritas, Inc. where she was CEO. Previously she was company group chair for Johnson & Johnson's biotech sector and during her time at the company, she was also executive vice president, global marketing and pharmaceuticals. Peterson has also held senior leadership positions at Biovail Corporation and Bristol Myers Squibb in marketing, sales and general management.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.